American Association for Cancer Research
00085472can130495-sup-0495.pdf (3.28 MB)

Supplementary Figures from Rapid Induction of Lung Adenocarcinoma by Fibroblast Growth Factor 9 Signaling through FGF Receptor 3

Download (3.28 MB)
journal contribution
posted on 2023-03-30, 21:50 authored by Yongjun Yin, Tomoko Betsuyaku, Joel R. Garbow, Jinbai Miao, Ramaswamy Govindan, David M. Ornitz

PDF file, 3363K, Expression of eGFP and Fgf9 following doxycycline induction for four days (S1); FGF9 promotes proliferation of cells in the bronchioalveolar duct junction (S2); Co-expression of FGFR3 and Sca-1 in the bronchioalveolar duct junction following induction of FGF9 (S3).



Fibroblast growth factors (FGF) are expressed in many non–small cell lung carcinoma (NSCLC) primary tumors and derived cell lines, and mutations in FGF receptor 3 (FGFR3) have been identified in human lung adenocarcinoma. FGF9 has been implicated in the pathogenesis of NSCLC by synergizing with EGFR pathways or by providing an escape pathway mediating resistance to EGFR inhibition. To model pathogenic mechanisms mediated by FGF signals, we have established a mouse model in which FGF9 expression can be induced in adult lung epithelium. Here, we show that induced expression of FGF9 in adult lung leads to the rapid proliferation of distal airway epithelial cells that express the stem cell marker, Sca-1, and the proximal and distal epithelial markers, Sftpc and CC10, the rapid formation of Sftpc-positive adenocarcinomas, and eventual metastasis in some mice. Furthermore, we have identified FGFR3 as the obligate receptor mediating the FGF9 oncogenic signal. These results identify an FGF9–FGFR3 signal as a primary oncogenic pathway for lung adenocarcinoma and suggest that this pathway could be exploited for customized therapeutic applications for both primary tumors and those that have acquired resistance to inhibition of other signaling pathways. Cancer Res; 73(18); 5730–41. ©2013 AACR.